Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $61000.0.

  • Seres Therapeutics' Cash from Financing Activities rose 10005.5% to $61000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year increase of 10347.57%. This contributed to the annual value of -$90.4 million for FY2024, which is 22603.31% down from last year.
  • Per Seres Therapeutics' latest filing, its Cash from Financing Activities stood at $61000.0 for Q3 2025, which was up 10005.5% from $1.2 million recorded in Q1 2025.
  • Seres Therapeutics' 5-year Cash from Financing Activities high stood at $98.0 million for Q3 2022, and its period low was -$110.9 million during Q3 2024.
  • For the 5-year period, Seres Therapeutics' Cash from Financing Activities averaged around $6.7 million, with its median value being $1.4 million (2023).
  • As far as peak fluctuations go, Seres Therapeutics' Cash from Financing Activities surged by 4465153.85% in 2023, and later plummeted by 778336.8% in 2024.
  • Over the past 5 years, Seres Therapeutics' Cash from Financing Activities (Quarter) stood at -$780000.0 in 2021, then skyrocketed by 689.36% to $4.6 million in 2022, then soared by 39.85% to $6.4 million in 2023, then crashed by 72.98% to $1.7 million in 2024, then plummeted by 96.49% to $61000.0 in 2025.
  • Its Cash from Financing Activities stands at $61000.0 for Q3 2025, versus $1.2 million for Q1 2025 and $1.7 million for Q4 2024.